Possible new role for angiotensin-converting enzyme inhibitors in treating glomerulonephritis
EMHJ-Eastern Mediterranean Health Journal. 2003; 9 (3): 399-406
en Inglés
| IMEMR
| ID: emr-158177
ABSTRACT
Serum transforming growth factor-beta [TGF-beta1] production was estimated for 10 patients with essential hypertension, 12 patients with glomerulonephritis [5 hypertensive and 7 normotensive] and 10 healthy controls. The glomerulonephritis group received angiotensin-converting enzyme inhibitor captopril 25-75 mg/day for 4 weeks. Blood urea, serum creatinine, 24-hour urinary protein and serum TGF-beta1 were then re-estimated. Urea and creatinine were significantly higher in the hypertension and glomerulonephritis groups than in the controls and also higher in the glomerulonephritis group than the hypertension group. TGF-beta1 was significantly higher in the glomerulonephritis groups than in the control and hypertension groups. TGF-beta1 and 24-hour urinary protein were significantly reduced in the glomerulonephritis group
Buscar en Google
Índice:
IMEMR (Mediterraneo Oriental)
Asunto principal:
Proteinuria
/
Nitrógeno de la Urea Sanguínea
/
Inmunoensayo
/
Captopril
/
Estudios de Casos y Controles
/
Enfermedad Crónica
/
Creatinina
/
Glomerulonefritis
/
Hipertensión
Límite:
Adulto
/
Femenino
/
Humanos
/
Masculino
Idioma:
Inglés
Revista:
East Mediterr Health J.
Año:
2003
Similares
MEDLINE
...
LILACS
LIS